Recognition and management of supraventricular tachyarrhythmias.
While the principles of drug management of supraventricular tachyarrhythmias have remained essentially unchanged, such treatment remains empirical in many patients. Recent advances in the understanding of electrophysiological mechanisms have not only rationalised treatment but dictated newer approaches to these and other arrhythmias.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D004077:Digoxin / Q000627:therapeutic use; D004554:Electric Countershock; D004562:Electrocardiography / Q000295:instrumentation; D005080:Exercise Test; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D010138:Pacemaker, Artificial; D011342:Procainamide / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D004077:Digoxin; D011433:Propranolol; D011802:Quinidine; D011342:Procainamide